Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

Engineering and Design of Chimeric Antigen Receptors

(2019) Sonia Guedan et al.   Molecular Therapy-Methods & Clinical Development

An immunoproteomic approach to characterize the CAR interactome and signalosome

(2019) Maria C. Ramello et al.   Science Signaling

Therapeutic gene editing in haematological disorders with CRISPR/Cas9

(2019) Trine I. Jensen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications

(2019) Sandra P. Susanibar Adaniya et al.   AMERICAN JOURNAL OF HEMATOLOGY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Delivery of CRISPR/Cas9 for therapeutic genome editing

(2019) Xiaojie Xu et al.   JOURNAL OF GENE MEDICINE

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

(2019) Rosalie M. Sterner et al.   Jove-Journal of Visualized Experiments

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

(2018) Jang Hwan Cho et al.   CELL

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia

(2018) Miriam Y. Kim et al.   CELL

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

(2018) Catherine M. Bollard et al.   JOURNAL OF CLINICAL ONCOLOGY

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

Rewiring T-cell responses to soluble factors with chimeric antigen receptors

(2018) ZeNan L Chang et al.   Nature Chemical Biology

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

(2018) Robert Q. Le et al.   ONCOLOGIST

Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells

(2018) Stephan Riesenberg et al.   Nature Communications

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

(2018) Joseph A. Fraietta et al.   NATURE

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

(2018) Marco Ruella et al.   NATURE MEDICINE

Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function

(2018) Alexander I. Salter et al.   Science Signaling

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

(2018) Jennifer N. Brudno et al.   BLOOD REVIEWS

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells

(2017) Iulia Diaconu et al.   MOLECULAR THERAPY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells

(2017) Germán G Gornalusse et al.   NATURE BIOTECHNOLOGY

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

(2017) Waseem Qasim et al.   Science Translational Medicine

A versatile system for rapid multiplex genome-edited CAR T cell generation

(2017) Jiangtao Ren et al.   Oncotarget

Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment

(2017) Zhenguang Wang et al.   Protein & Cell

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

(2016) Elise A. Chong et al.   BLOOD

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells

(2016) Xiaojuan Liu et al.   CELL RESEARCH

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

(2016) Jiangtao Ren et al.   CLINICAL CANCER RESEARCH

273. Genome Editing Using CRISPR-Cas9 to Increase the Therapeutic Index of Antigen-Specific Immunotherapy in Acute Myeloid Leukemia

(2016) Miriam Y. Kim et al.   MOLECULAR THERAPY

In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration

(2016) Keiichiro Suzuki et al.   NATURE

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies

(2015) Laurent Poirot et al.   CANCER RESEARCH

TRUCKs: the fourth generation of CARs

(2015) Markus Chmielewski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Potential pitfalls of CRISPR/Cas9-mediated genome editing

(2015) Rongxue Peng et al.   FEBS Journal

Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining

(2015) Takeshi Maruyama et al.   NATURE BIOTECHNOLOGY

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD

(2015) A. Kunkele et al.   Cancer Immunology Research

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer

(2014) B Berdien et al.   GENE THERAPY

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

(2014) I Pizzitola et al.   LEUKEMIA

CRISPR-Cas systems for editing, regulating and targeting genomes

(2014) Jeffry D Sander et al.   NATURE BIOTECHNOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR–Cas9 system

(2014) R. Torres et al.   Nature Communications

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

(2013) A. Mardiros et al.   BLOOD

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors

(2013) H. Torikai et al.   BLOOD

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

(2013) David S. Ritchie et al.   MOLECULAR THERAPY

HLA Engineering of Human Pluripotent Stem Cells

(2013) Laura Riolobos et al.   MOLECULAR THERAPY

RNA-Guided Human Genome Engineering via Cas9

(2013) P. Mali et al.   SCIENCE

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

(2012) H. Torikai et al.   BLOOD

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Mutation in the TCRα subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCRαβ+ T cells

(2011) Neil V. Morgan et al.   JOURNAL OF CLINICAL INVESTIGATION

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

(2010) V Hoyos et al.   LEUKEMIA

A TALE nuclease architecture for efficient genome editing

(2010) Jeffrey C Miller et al.   NATURE BIOTECHNOLOGY

Genome editing with engineered zinc finger nucleases

(2010) Fyodor D. Urnov et al.   NATURE REVIEWS GENETICS

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sequence- and Structure-Specific RNA Processing by a CRISPR Endonuclease

(2010) Rachel E. Haurwitz et al.   SCIENCE

The promise and potential pitfalls of chimeric antigen receptors

(2009) Michel Sadelain et al.   CURRENT OPINION IN IMMUNOLOGY

A Simple Cipher Governs DNA Recognition by TAL Effectors

(2009) M. J. Moscou et al.   SCIENCE

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD

Progress and prospects: Zinc-finger nucleases as gene therapy agents

(2008) D Carroll   GENE THERAPY

Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-?? Receptor

(2008) Aaron E. Foster et al.   JOURNAL OF IMMUNOTHERAPY